Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
BioConferenceLive

Market for MicroRNA Tools and Services Expected to More than Double

By BiotechDaily International staff writers
Posted on 16 Sep 2013
Due to the rapid growth in microRNA (miRNA) research, the markets for reagents and instrumentation in this field as well as for miRNA service providers are expected to more than double over the next several years.

The growth of therapeutic and diagnostic enterprises, higher research funding, and increased outsourcing to contract research organizations should present immense opportunities for the miRNA tools and services market.

Data released in the new Frost & Sullivan (Mountain View, CA, USA) report "Global Analysis of MicroRNA Tools and Services Market" revealed that the market for reagents and instrumentation earned revenues of 110.0 million USD in 2012 and estimated this to more than double to reach 247.7 USD million in 2017.

The miRNA services market, which caters to academic and research institutes, core facilities, and pharmaceutical and biotech companies, earned revenues of 35.1 million USD in 2012, and this is expected to grow to 63.3 million USD in 2017.

Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays, and functional tools, qRT PCR remains the fastest growing, while microarray is gradually being replaced by next-generation sequencing platforms.

"As miRNA research evolves globally and more efficient products are required, the space is burgeoning with technology innovations," said Divyaa Ravishankar, senior research analyst at Frost & Sullivan. "Strategic alliances for product development are taking place, resulting in novel kits for qPCR and new mimics and inhibitors that help researchers shorten their project timeline and get more funding. To sustain product value until then, market participants must continue to offer technology improvements and differentiated features, and strategically compete without making deep pricing cuts that may irreversibly damage market potential. Providing complete workflow solutions and discounts when a customer purchases products along with several different portfolios will simplify purchasing and attract new customers."

Related Links:

Frost & Sullivan



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.